| What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. | |
| | |
MedLine Citation:
|
PMID: 21060068 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Aggressive blood pressure (BP) control has been advocated in patients with acute coronary syndrome, but few data exist in this population relative to cardiovascular outcomes. METHODS AND RESULTS: We evaluated 4162 patients enrolled in the PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial (acute coronary syndrome patients randomized to pravastatin 40 mg versus atorvastatin 80 mg). The average follow-up BP (systolic and diastolic) was categorized into 10-mm Hg increments. The primary outcome was a composite of death due to any cause, myocardial infarction, unstable angina requiring rehospitalization, revascularization after 30 days, and stroke. The secondary outcome was a composite of death due to coronary heart disease, nonfatal myocardial infarction, or revascularization. The relationship between BP (systolic or diastolic) followed a J- or U-shaped curve association with primary, secondary, and individual outcomes, with increased events rates at both low and high BP values, both unadjusted and after adjustment for baseline variables, baseline C-reactive protein, and on-treatment average levels of low-density lipoprotein cholesterol. A nonlinear Cox proportional hazards model showed a nadir of 136/85 mm Hg (range 130 to 140 mm Hg systolic and 80 to 90 mm Hg diastolic) at which the incidence of primary outcome was lowest. The curve was relatively flat for systolic pressures of 110 to 130 mm Hg and diastolic pressures of 70 to 90 mm Hg. CONCLUSIONS: After acute coronary syndrome, a J- or U-shaped curve association existed between BP and the risk of future cardiovascular events, with lowest event rates in the BP range of approximately 130 to 140 mm Hg systolic and 80 to 90 mm Hg diastolic and a relatively flat curve for systolic pressures of 110 to 130 mm Hg and diastolic pressures of 70 to 90 mm Hg, which suggests that too low of a pressure (especially <110/70 mm Hg) may be dangerous. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00382460. |
| | |
Authors:
|
Sripal Bangalore; Jie Qin; Sarah Sloan; Sabina A Murphy; Christopher P Cannon; |
Related Documents
:
|
10977788 - Lack of seasonal variation in blood pressure in patients on hemodialysis in a north ame... 1375678 - Syst-eur--a multicenter trial on the treatment of isolated systolic hypertension in the... 19683638 - Usual versus tight control of systolic blood pressure in non-diabetic patients with hyp... 12376438 - Using vital signs to diagnose impaired consciousness: cross sectional observational study. 22632938 - Differential calcium handling in two canine models of right ventricular pressure overload. 12160188 - Aortic pulse pressure and extent of coronary artery disease in percutaneous translumina... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-11-08 |
Journal Detail:
|
Title: Circulation Volume: 122 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-24 Completed Date: 2010-12-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: 2142-51 Citation Subset: AIM; IM |
Affiliation:
|
New York University School of Medicine, New York, NY, USA. |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00382460 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Coronary Syndrome
/
drug therapy*,
mortality,
physiopathology Adult Aged Anticholesteremic Agents / administration & dosage*, adverse effects Blood Pressure / drug effects*, physiology Female Follow-Up Studies Heptanoic Acids / administration & dosage*, adverse effects Humans Hypertension / mortality, prevention & control Incidence Male Middle Aged Myocardial Infarction / drug therapy*, mortality, physiopathology Pravastatin / administration & dosage*, adverse effects Prognosis Proportional Hazards Models Pyrroles / administration & dosage*, adverse effects Risk Factors Thrombolytic Therapy Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Heptanoic Acids; 0/Pyrroles; 110862-48-1/atorvastatin; 81093-37-0/Pravastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The potential role of androgenesis in cytoplasmic-nuclear phylogenetic discordance.
Next Document: Factors associated with pulseless electric activity versus ventricular fibrillation: the Oregon sudd...